Shionogi USA in the News
May 14, 2001
Shionogi & Co., Ltd.

Establishment of Shionogi USA, Inc.
Shionogi & Co., Ltd. (Shionogi) established a wholly owned subsidiary named Shionogi USA, Inc., where pharmaceutical development in the US will be carried out as of May 15, 2001.

As Shionogi’s business plan announced in last April describes, Shionogi recognizes that developing compounds discovered at Shionogi Research Laboratories globally is one of the most important strategies for Shionogi’s future.

Shionogi USA, Inc. will be a base of pharmaceutical development in the US, which will proceed with the development by itself (facilitating Contract Research Organization), and/or by entering into an alliance with some partners depending on the compounds to be developed. In addition, it is planning to market in-house products in the future.

The following is the profile of the US-subsidiary:

1. Corporate Name: Shionogi USA, Inc.

2. Objective: Pharmaceutical development/Conducting clinical trials

3. Date of Incorporation: February 15, 2001

4. Operation starting date: May 15, 2001

5. Capital: US$1 millionNumber of issued stock: One thousand (1000) sharesShionogi’s 100% owned subsidiary (Registered in Delaware)

6. Location:100 Campus Drive Florham Park, NJ 07932, USA Tel 973-966-6900 Fax 973-966-2820

7. Representative Director: Reiji Takeda, Ph.D., Director of the Board of Shionogi & Co., Ltd., General Manger of International Business Division

8. Initial Number of employees: Eight (8)